We will briefly discuss the BCL-2 family of proteins that underlie AML pathogenesis and treatment resistance, as well as the therapeutic potential of targeting CDKs that regulate transcription, focusing on CDK9 inhibition. The gene discussed is BCL2; the disease is acute myeloid leukemia.